Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11840579 Bispecific antibodies that bind to CD38 and CD3

Patent 11840579 was granted and assigned to Xencor on December, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

John Desjarlais0

Seung Chu0

Matthew Bernett0

Gregory Moore0

Date of Patent

December 12, 2023

0

Patent Application Number

170862130

Date Filed

October 30, 2020

0

Patent Citations

US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof

0

US Patent 6884869 Pentapeptide compounds and uses related thereto

0

US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor

0

US Patent 7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor

0

US Patent 8946387 FcγRIIB specific antibodies and methods of use thereof

0

US Patent 9181334 Pharmaceutical composition for treatment and/or prophylaxis of cancer

0

US Patent 9822181 Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

0

US Patent 9856327 Heterodimeric antibodies to CD3 X CD123

0

...

Patent Primary Examiner

0

Patent abstract

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11840579 Bispecific antibodies that bind to CD38 and CD3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool